Natera (NTRA) Expected to Announce Quarterly Earnings on Wednesday

Natera (NASDAQ:NTRA) is projected to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $447.91 million for the quarter.

Natera Stock Performance

NTRA stock opened at $169.38 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market capitalization of $22.36 billion, a price-to-earnings ratio of -96.24 and a beta of 1.66. Natera has a 1 year low of $68.03 and a 1 year high of $183.00. The stock’s fifty day moving average is $167.86 and its two-hundred day moving average is $143.93.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Guggenheim lifted their price target on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Craig Hallum lifted their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, The Goldman Sachs Group boosted their target price on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $165.88.

Insider Activity

In other Natera news, Director Roelof Botha sold 87,473 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total value of $14,793,433.76. Following the sale, the director now directly owns 1,224,787 shares in the company, valued at $207,135,977.44. This represents a 6.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 295,772 shares of company stock worth $49,741,699. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.